Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: Difference exists in the strength of surrogacy in various trial settings
Số trang: 13
Loại file: pdf
Dung lượng: 2.83 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
This study aims to systematically validate the performance of surrogate endpoints in phase II and III clinical trials for NSCLC patients under various trial settings. A literature search retrieved all registered phase II and III trials of NSCLC patients in which OS, with at least one of ORR and PFS, were reported. Associations between surrogate and true endpoints were assessed on two levels.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Surrogate endpoint Meta-analysis Non-small cell lung cancer Targeted therapy Patient-level analysesTài liệu có liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 179 0 0 -
6 trang 171 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 150 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 136 0 0 -
12 trang 103 0 0
-
19 trang 81 0 0
-
17 trang 71 0 0
-
9 trang 48 0 0
-
9 trang 43 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 43 0 0